Journal profile · Chemistry, Multidisciplinary
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
ISSN 0004-4172 · GERMANY · Monthly · Founded 1951
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH: impact factor 1.9 (journal website); subscription journal; APC about USD 3,620; review 4–8 weeks (community reports); community-reported acceptance: easy; 103 articles a year.
Scope
Aims, scope and focus
By OpenAlex counts of its recent articles, ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH's largest topics are Synthesis and biological activity, Analytical Methods in Pharmaceuticals and Antibiotics Pharmacokinetics and Efficacy, together about 28.1% of its articles. Its main subfields are Organic Chemistry. (generated from OpenAlex topic counts and CAS ranking data)
Target ReadershipDrug Research is intended for scientists, clinicians, and professionals involved in drug discovery, drug development, translational medicine, pharmacology, toxicology, and the evaluation of therapeutic compounds. It serves researchers working with both novel and established drug molecules, as well as those engaged in clinical trials, industrial investigations, and the quantitative assessment of drug efficacy and safety.Journal Purpose and MissionDrug Research (formerly Arzneimittelforschung) is an international peer‑reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. The journal also addresses the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials.Types of Articles PublishedDrug Research publishes the following article types, Original Article, Review, Short Communication, Commentary, Letter, Controversy, and Opinion Paper.Publication FrequencyDrug Research publishes 12 issues per annum.Subject and Content ScopeThe journal presents research related to novel and established drug molecules and the evaluation of new drug development. Its scope includes translational medicine and the application of biological discoveries to clinical drug development, as well as analytics applied to clinical trials, chemistry and biochemistry, clinical and experimental pharmacology, drug interactions, efficacy testing, pharmacodynamics, pharmacokinetics, teratology, and toxicology. It also encompasses the mathematical and statistical methods used to evaluate results from industrial investigations and clinical trials.
From the journal's Aims & Scope
Research area (LetPub): Chemistry, Multidisciplinary
Editor-in-chief Thomas GudermannPublisher website
Editorial board by country: 2 in mainland China (about 13%); most named Germany 8, Mainland China 2, Switzerland 2, South Korea 1, France 1 (15 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Synthesis and biological activityChemistry10.8%
- Analytical Methods in PharmaceuticalsChemistry9.7%
- Antibiotics Pharmacokinetics and EfficacyMedicine7.6%
- Pharmaceutical studies and practicesMedicine5.9%
- Synthesis and Characterization of Heterocyclic CompoundsChemistry5.9%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics5.8%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance5.3%
- Synthesis and Biological EvaluationChemistry4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
Indexed in: no record yet.
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
SSCIEmbasePublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 1.9Publisher website ·
- h-index
- 57OpenAlex ·
- i10-index
- 617OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year
- 103LetPub ·
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Peer review
- Single-anonymous peer reviewPublisher website · model-extracted
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | EUR 3,390 / USD 3,620 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 3–6
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Highlights
- Optional
- Graphical abstract
- Optional
- Cover letter
- Required
- Not considered
- bioequivalence studies; studies on novel compounds which are only tested in vitro
Article types accepted13
- commentariesC. Commentaries They usually follow the article that they discuss, have no special structure and are usually invited.Length not stated
- commentaryDrug Research publishes the following article types, Original Article, Review, Short Communication, Commentary, Letter, Controversy, and Opinion Paper.Length not stated
- controversiesD. Opinion Papers, Controversies The structure of these papers will vary from an original paper according to the nature of the topic and argument. Opinion paper…Length not stated
- letterDrug Research publishes the following article types, Original Article, Review, Short Communication, Commentary, Letter, Controversy, and Opinion Paper.Length not stated
- lettersF. Letters This article type has been introduced to encourage authors to engage in a free exchange of ideas.Length not stated
- opinionDrug Research publishes the following article types, Original Article, Review, Short Communication, Commentary, Letter, Controversy, and Opinion Paper.Length not stated
- opinion papersD. Opinion Papers, Controversies The structure of these papers will vary from an original paper according to the nature of the topic and argument. Opinion paper…Length not stated
- original articleDrug Research publishes the following article types, Original Article, Review, Short Communication, Commentary, Letter, Controversy, and Opinion Paper.Length not stated
- original articlesA. Original Articles Original papers should deal with investigations and results of high scientific value which have not been published previously.Length not stated
- reviewDrug Research publishes the following article types, Original Article, Review, Short Communication, Commentary, Letter, Controversy, and Opinion Paper.Length not stated
- reviewsB. Reviews Reviews deal with previous research on a certain topic and serve to summarize current findings on the topic so far.Length not stated
- short communicationDrug Research publishes the following article types, Original Article, Review, Short Communication, Commentary, Letter, Controversy, and Opinion Paper.Length not stated
- short communicationsE. Short Communications Short Communications are completed projects of smaller scope and should contain new clinical and experimental data of immediate interest…Length not stated
Policy excerpts from the journal's websiteConflicts of interest, Publication ethics, Open access, Preprints, Trial registration / reporting guidelines
- Conflicts of interest Conflict of Interest
Conflict of interest declaration required for all authors during submission; failure may result in non-publication. Model summary
Please state the conflicts of interest of all authors during the online submission process. Failure to do so or an incomplete declaration may result in non-publication.
Source ↗Publisher website ·- Publication ethics
Ethics: proof of adherence to Declaration of Helsinki or local ethics committee approval for human research; compliance with Guide for the Care and Use of Laboratory Animals or ethics committee approval for animal research. Model summary
Please provide proof that the terms of the latest version of the “World Medical Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects” have been adhered to or provide approval of your local ethics committee.
Source ↗Publisher website ·- Open access Publish Open Access
Hybrid Open Access available via APC payment; price list on Thieme website. Model summary
Authors of articles for all Thieme subscription journals – including, of course, Drug Research - have the option of paying an article processing charge (APC) so that their articles will be published on an Open Access basis. Learn more about Thieme’s Open Access program by visiting https://www.thieme.com/en-us/who-we-serve/authors/journals/open-access. For the current pricing, please go to “APC” an…
Source ↗Publisher website ·- Preprints Preprint Server Statement
Preprints allowed (Research Square, arXiv, medRxiv, etc.); must note in cover letter, state updates, cite preprint with DOI; discouraged from depositing new versions until final decision; can update preprint 12 months after publication. Model summary
Drug Research encourages the submission of manuscripts that have been deposited in an initial draft version in preprint repositories such as Research Square, arXiv, and medRxiv. Drafts of short conference abstracts or degree theses posted on the website of the degree-granting institution, and draft manuscripts deposited on authors’ or institutional websites are also welcome. All other prior public…
Source ↗Publisher website ·- Trial registration / reporting guidelines
Clinical trial registration required before recruitment of first subject; must be registered at an official registry recognised by ICMJE (e.g., ClinicalTrials.gov or WHO ICTRP primary registries). Model summary
Clinical trials must be registered before recruitment of the first subject.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Country or region
- GERMANY
- Frequency
- Monthly
- Founded
- 1951
- ISSN
- 0004-4172
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
What is the impact factor of ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH?
The journal's website gives an impact factor of 1.9; this is the journal's own figure, as LetPub lists none for it; h-index 57.
How long does peer review take at ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH?
Authors report an average review time of 4–8 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 3–6; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Highlights: Optional; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH based?
Of the 15 board members whose country the journal's board page names, 2 (about 13%) are in mainland China; the countries named most often are Germany (8), Mainland China (2) and Switzerland (2). Counted from the institutions listed on the board page; for reference only.
Which databases index ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH?
The journal's website lists SSCI and Embase; that list has not been checked against each database.
Is ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH open access, and what is the APC?
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH is a subscription journal. APC about USD 3,620.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .